With European Approval Imminent, J&J/Bayer File Rivaroxaban In The U.S.
This article was originally published in The Pink Sheet Daily
Executive Summary
Novel anticoagulant for orthopedic surgery poised to reach market before Pfizer, Bristol, Astellas and Daiichi Sankyo compounds.